百济神州：百泽安获欧洲药品管理局人用药品委员会积极意见

智通财经2025-07-29

7月29日，据百济神州官微消息，7月28日，公司宣布欧洲药品管理局(EMA)人用药品委员会(CHMP)发布积极意见，推荐批准百泽安®(替雷利珠单抗)联合含铂化疗用于存在高复发风险的可切除非小细胞肺癌(NSCLC)成人患者的术前新辅助治疗，并在术后继续使用替雷利珠单抗单药进行辅助治疗。该推荐基于3期RATIONALE-315研究(NCT04379635)结果。据介绍，替雷利珠单抗已在欧盟获批的肺癌...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2555866160?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2025-07-29 10:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555866160","market":"hk","top_or_hot":-1,"title":"百济神州：百泽安获欧洲药品管理局人用药品委员会积极意见","media":"智通财经","content":"<div>\n<p>7月29日，据百济神州官微消息，7月28日，公司宣布欧洲药品管理局(EMA)人用药品委员会(CHMP)发布积极意见，推荐批准百泽安®(替雷利珠单抗)联合含铂化疗用于存在高复发风险的可切除非小细胞肺癌(NSCLC)成人患者的术前新辅助治疗，并在术后继续使用替雷利珠单抗单药进行辅助治疗。该推荐基于3期RATIONALE-315研究(NCT04379635)结果。据介绍，替雷利珠单抗已在欧盟获批的肺癌...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1322972.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州：百泽安获欧洲药品管理局人用药品委员会积极意见</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州：百泽安获欧洲药品管理局人用药品委员会积极意见\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-29 10:45 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1322972.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月29日，据百济神州官微消息，7月28日，公司宣布欧洲药品管理局(EMA)人用药品委员会(CHMP)发布积极意见，推荐批准百泽安®(替雷利珠单抗)联合含铂化疗用于存在高复发风险的可切除非小细胞肺癌(NSCLC)成人患者的术前新辅助治疗，并在术后继续使用替雷利珠单抗单药进行辅助治疗。该推荐基于3期RATIONALE-315研究(NCT04379635)结果。据介绍，替雷利珠单抗已在欧盟获批的肺癌...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1322972.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1322972.html","article_id":"2555866160","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555866160","pubTimestamp":1753757135,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"7月29日，据$百济神州$官微消息，7月28日，公司宣布欧洲药品管理局人用药品委员会发布积极意见，推荐批准百泽安联合含铂化疗用于存在高复发风险的可切除非小细胞肺癌成人患者的术前新辅助治疗，并在术后继续使用替雷利珠单抗单药进行辅助治疗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688235":"百济神州","06160":"百济神州","BK1588":"回港中概股","BK4526":"热门中概股","ONC":"百济神州","BK4139":"生物科技","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1583":"高瓴概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0239":"医药制造","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK4087":"商业印刷","BK1161":"生物科技","BK1500":"做空集合股"},"translate_title":"Changes in Hong Kong stocks | BeiGene (06160) rose more than 3% Baizean ® Received positive opinion from the European Medicines Agency CHMP","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/94f7c53ec9eb51b3feb3a98f37dc072c","symbols_score_info":{"688235":1,"06160":1,"ONC":1},"content_text":"7月29日，据百济神州官微消息，7月28日，公司宣布欧洲药品管理局(EMA)人用药品委员会(CHMP)发布积极意见，推荐批准百泽安®(替雷利珠单抗)联合含铂化疗用于存在高复发风险的可切除非小细胞肺癌(NSCLC)成人患者的术前新辅助治疗，并在术后继续使用替雷利珠单抗单药进行辅助治疗。该推荐基于3期RATIONALE-315研究(NCT04379635)结果。据介绍，替雷利珠单抗已在欧盟获批的肺癌相关适应症包括：用于鳞状NSCLC患者一线治疗；用于PD-L1高表达的非鳞状NSCLC患者一线治疗；用于既往接受过含铂治疗的局部晚期或转移性NSCLC患者治疗；用于广泛期小细胞肺癌患者一线治疗。此外，获批适应症还包括：用于胃或胃食管结合部腺癌患者一线治疗；用于不可切除的食管鳞状细胞癌(ESCC)患者一线治疗；用于既往接受过含铂化疗的ESCC患者二线治疗；用于鼻咽癌患者一线治疗。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555866160","isCrawlerRequest":true}